Meloxicam Tablet
Product Images NDC 11788-099

This description on Meloxicam Tablets provides details on the strength of 15 mg, container size of 1000s, and bottle size of 500 cc. Each tablet contains 15 mg of meloxicam. The instructions recommend storing in a tight container in a dry place, away from children. The dosage information should be read from the accompanying prescribing information. The tablets are manufactured for AiPing Pharmaceutical, Inc. in Hauppauge, NY, and should be dispensed with the accompanying medication guide.*

This is a description of Meloxicam Tablets, USP 7.5 mg. The tablets are contained in a bottle size of 500 cc with a total count of 1000 tablets. Each tablet contains 7.5 mg of meloxicam. The tablets should be dispensed in a tight container and kept out of reach of children. The medication is manufactured by AiPing Pharmaceutical, Inc. in Hauppauge, NY. The prescription is for 1000 tablets and should be accompanied by the prescribing information and medication guide.*

This text provides information on the use of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). It is advised to avoid taking NSAIDs before or after a heart surgery called a coronary artery bypass graft (CABG). Furthermore, it is recommended not to take NSAIDs after a recent heart attack without consultation from a healthcare provider as it may increase the risk of another heart attack.*

This text provides important information about the warning signs and risk factors associated with the use of NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). It highlights various factors such as a history of stomach ulcers, use of certain medications, dosage of NSAIDs, lifestyle choices like smoking and alcohol consumption, as well as age and health conditions that can potentially lead to ulcers or bleeding issues. It emphasizes the need to be aware of these risks to ensure safe usage of these drugs.*

This text contains information about possible symptoms such as shortness of breath, slurred speech, chest pain, swelling of the face or throat, and weakness in one part or side of the body. These symptoms could indicate a medical emergency or condition that requires immediate attention.*

This text appears to be descriptions of potential symptoms or signs that may indicate various medical conditions. These include nausea, fatigue, diarrhea, itching, jaundice (yellow skin or eyes), indigestion, flu-like symptoms, vomiting blood, blood in bowel movements, unexplained weight gain, skin rash with fever, and swelling of arms, legs, hands, and feet. These symptoms could be related to different health issues, and it is advisable to consult a healthcare provider for proper evaluation and diagnosis.*

This is a table showing adverse events (%) occurring in at least 22% of Meloxicam patients during a 12-week osteoarthritis placebo- and active-controlled trial. The table includes data on various adverse events comparing Placebo, Meloxicam (15mg daily), Meloxicam (100mg daily), and Diclofenac (75mg daily) groups. The adverse events reported cover gastrointestinal issues, abdominal pain, diarrhea, accidents at home, edema, falls, influenza-like symptoms, central and peripheral nervous system effects, respiratory issues, and skin reactions. The table also mentions the combined WHO preferred terms for some of the adverse events.*

This is a list of adverse events occurring in more than 2% of patients taking meloxicam in two 12-week placebo-controlled trials for rheumatoid arthritis. Common adverse events include gastrointestinal disorders such as dyspeptic signs and symptoms, abdominal pain, and nausea. Other reported events include infection, musculoskeletal disorders, headaches, and rashes. These events were documented in trials involving 469 to 481 patients receiving meloxicam in daily doses of 7.5mg or 15mg.*

This document appears to be a list of possible side effects or symptoms associated with a medication or medical condition. The list includes various symptoms related to different parts of the body such as allergic reactions, fatigue, weight changes, cardiovascular issues like hypertension, gastrointestinal problems, nervous system disorders including convulsions and tremors, as well as skin issues like alopecia and urticaria. It also mentions potential effects on special senses, the urinary system, and metabolic functions. This list may be used by healthcare professionals to understand and monitor the potential adverse effects of a treatment.*

This is a table displaying Adverse Events (%) occurring in meloxicam patients in 4 to 6 weeks and 6-month active-controlled osteoarthritis trials. The table lists various adverse events such as Gastrointestinal issues, abdominal pain, constipation, diarrhea, dyspepsia, and others with the percentage of occurrence for each adverse event. It provides valuable information on the frequency of different side effects associated with meloxicam use in controlled trials.*

This is a useful description of potential drug interactions involving the medication meloxicam. It highlights how meloxicam can impact the efficacy and toxicity of other drugs such as lithium, methotrexate, cyclosporine, NSAIDs, salicylates, and pemetrexed. It emphasizes the need for close monitoring of patients for signs of toxicity and provides specific recommendations for managing these interactions to ensure patient safety and treatment effectiveness.*

This text provides valuable information on clinically significant drug interactions with Meloxicam. It discusses potential interactions with drugs that interfere with hemostasis, such as anticoagulants, and the increased risk of bleeding. It also touches on the concomitant use of NSAIDs and aspirin, emphasizing the importance of monitoring patients for signs of bleeding. Additionally, it highlights how NSAIDs may impact the antihypertensive effects of certain medications like ACE inhibitors and diuretics. Overall, the text emphasizes the need for close monitoring and intervention when using Meloxicam alongside other medications to ensure patient safety.*